Due to the improved subacute outcomes observed with CR2-fH treatment compared to CR2-Crry treatment of C3 deficiency, we further investigated the effect of CR2-fH treatment by analysis of gene expression profiles 3 days after MCAO. The gene discussed is C3; the disease is hyperinsulinemic hypoglycemia, familial, 4.